Nektar Therapeutics (NASDAQ:NKTR) shares saw an uptick in trading volume on Friday . 2,336,979 shares were traded during mid-day trading, an increase of 99% from the previous session’s volume of 1,175,424 shares.The stock last traded at $17.30 and had previously closed at $16.10.

Several research firms recently commented on NKTR. Zacks Investment Research cut Nektar Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 2nd. Brean Capital restated a “buy” rating on shares of Nektar Therapeutics in a research note on Wednesday, May 4th. Finally, Piper Jaffray Cos. restated a “buy” rating and set a $17.00 price objective on shares of Nektar Therapeutics in a research note on Wednesday, May 4th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $18.20.

The company’s market cap is $2.36 billion. The firm has a 50 day moving average price of $15.03 and a 200 day moving average price of $14.02.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.09. The company earned $58.88 million during the quarter, compared to analyst estimates of $43.78 million. During the same period in the prior year, the business earned $0.25 EPS. The business’s revenue for the quarter was down 45.9% on a year-over-year basis. On average, equities analysts predict that Nektar Therapeutics will post ($0.95) earnings per share for the current fiscal year.

In other Nektar Therapeutics news, CAO Jillian B. Thomsen sold 100,000 shares of Nektar Therapeutics stock in a transaction on Monday, July 11th. The shares were sold at an average price of $15.09, for a total transaction of $1,509,000.00. Following the completion of the sale, the chief accounting officer now owns 106,809 shares of the company’s stock, valued at approximately $1,611,747.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Howard W. Robin sold 2,170 shares of Nektar Therapeutics stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $13.58, for a total transaction of $29,468.60. Following the sale, the chief executive officer now directly owns 19,103 shares of the company’s stock, valued at approximately $259,418.74. The disclosure for this sale can be found here.

Other hedge funds have added to or reduced their stakes in the company. Nationwide Fund Advisors raised its stake in Nektar Therapeutics by 2.1% in the fourth quarter. Nationwide Fund Advisors now owns 86,558 shares of the biopharmaceutical company’s stock worth $1,459,000 after buying an additional 1,781 shares in the last quarter. State of Tennessee Treasury Department acquired a new stake in Nektar Therapeutics during the fourth quarter worth approximately $1,736,000. Comerica Bank raised its stake in Nektar Therapeutics by 0.6% in the fourth quarter. Comerica Bank now owns 135,326 shares of the biopharmaceutical company’s stock worth $1,992,000 after buying an additional 828 shares in the last quarter. New York State Common Retirement Fund raised its stake in Nektar Therapeutics by 1.9% in the fourth quarter. New York State Common Retirement Fund now owns 177,127 shares of the biopharmaceutical company’s stock worth $2,985,000 after buying an additional 3,300 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in Nektar Therapeutics by 6.5% in the fourth quarter. Rhumbline Advisers now owns 179,459 shares of the biopharmaceutical company’s stock worth $3,024,000 after buying an additional 10,900 shares in the last quarter.

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.